Galectin Therapeutics (Galectin Therapeutics) Equity-to-Asset

: -2.14 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Galectin Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-60.24 Mil. Galectin Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $28.20 Mil.

The historical rank and industry rank for Galectin Therapeutics's Equity-to-Asset or its related term are showing as below:

GALT' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.14 Med: 0.76 Max: 0.95
Current: -2.14

During the past 13 years, the highest Equity to Asset Ratio of Galectin Therapeutics was 0.95. The lowest was -2.14. And the median was 0.76.

GALT's Equity-to-Asset is ranked worse than
94.25% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs GALT: -2.14

Galectin Therapeutics Equity-to-Asset Historical Data

The historical data trend for Galectin Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.94

0.82

0.06

-1.51

-2.14

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset																-1.51	-2.11	-2.55	-2.30	-2.14

Competitive Comparison

For the Biotechnology subindustry, Galectin Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galectin Therapeutics Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Equity-to-Asset falls into.

Galectin Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Galectin Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-60.241	/	28.2
	=

Galectin Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-60.241	/	28.2
	=

Galectin Therapeutics (NAS:GALT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Galectin Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (Galectin Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

PHPN:Germany

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Executives

Kary Eldred	director	2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman	director	712 LAKEWAY DRIVE, KELLER TX 76248
Zordani Richard A. Jr.	director	467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
10x Fund, L.p.	10 percent owner	1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz	director	235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio	director	5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein	director, 10 percent owner	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes	officer: Chief Medical Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Joel Lewis	director	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Harold H. Shlevin	director, officer: Chief Executive Officer	C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Jack W Callicutt	officer: Chief Financial Officer	75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
Marc Rubin	director	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
James C Czirr	director	4908 SOUTH ASHTON COURT, SPOKANE WA 99223
Peter G Traber	director, officer: President and CEO	430 THAMER LANE, HOUSTON TX 77025